

EQR DATA DICTIONARY—APPENDIX F.  
RATE UNITS

Rate units	Definition
\$/KV .....	dollars per kilovolt.
\$/KVA .....	dollars per kilovolt amperes.
\$/KVR .....	dollars per kilovar.
\$/KW .....	dollars per kilowatt.
\$/KWH .....	dollars per kilowatt hour.
\$/KW-DAY .....	dollars per kilowatt day.
\$/KW-MO .....	dollars per kilowatt month.
\$/KW-WK .....	dollars per kilowatt week.
\$/KW-YR .....	dollars per kilowatt year.
\$/MW .....	dollars per megawatt.
\$/MWH .....	dollars per megawatt hour.
\$/MW-DAY .....	dollars per megawatt day.
\$/MW-MO .....	dollars per megawatt month.
\$/MW-WK .....	dollars per megawatt week.
\$/MW-YR .....	dollars per megawatt year.
\$/MVAR-YR .....	dollars per megavar year.
\$/RKVA .....	dollars per reactive kilovar amperes.
CENTS .....	cents.
CENTS/KVR .....	cents per kilovolt amperes.
CENTS/KWH .....	cents per kilowatt hour.
FLAT RATE .....	rate not specified in any other units.

[FR Doc. E8-184 Filed 1-9-08; 8:45 am]

BILLING CODE 6717-01-P

## FEDERAL HOUSING FINANCE BOARD

Sunshine Act Meeting Notice;  
Announcing a Partially Open Meeting  
of the Board of Directors

**TIME AND DATE:** The open meeting of the Board of Directors is scheduled to begin at 10 am on Tuesday, January 15, 2008. The closed portion of the meeting will follow immediately the open portion of the meeting.

**PLACE:** Board Room, First Floor, Federal Housing Finance Board, 1625 Eye Street, NW., Washington, DC 20006.

**STATUS:** The first portion of the meeting will be open to the public. The final portion of the meeting will be closed to the public.

**MATTER TO BE CONSIDERED AT THE OPEN PORTION:** Federal Home Loan Bank of San Francisco—Waiver of Certain AHP Regulations to Permit Refinancing/Modification of Subprime Mortgage Loans.

**MATTER TO BE CONSIDERED AT THE CLOSED PORTION:** Periodic Update of Examination Program Development and Supervisory Findings.

**CONTACT PERSON FOR MORE INFORMATION:** Shelia Willis, Paralegal Specialist, Office of General Counsel, at 202-408-2876 or [williss@fhfb.gov](mailto:williss@fhfb.gov).

Dated: January 8, 2008.

By the Federal Housing Finance Board.

Neil R. Crowley,

Acting General Counsel.

[FR Doc. 08-85 Filed 1-8-08; 3:59 pm]

BILLING CODE 6725-01-P

## FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and  
Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center Web site at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 5, 2008.

**A. Federal Reserve Bank of Kansas City** (Todd Offerbacker, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Young Partners, L.P., and its general partner, Young Corporation, and Citizens Bancshares Company, all of Chillicothe, Missouri, and First Community Bancshares, Inc., and FCB Acquisition Corp., both of Overland Park, Kansas;* to acquire NKC Bancshares, Inc., and thereby indirectly acquire Norbank, both of North Kansas City, Missouri. In connection with this application, FCB Acquisition Corp. has

applied to become a bank holding company by merging with NKC Bancshares Inc.

Board of Governors of the Federal Reserve System, January 7, 2008.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E8-262 Filed 1-9-08; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND  
HUMAN SERVICESCenters for Disease Control and  
Prevention

[60Day-08-0008]

Proposed Data Collections Submitted  
for Public Comment and  
Recommendations

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404-639-5960 and send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to [omb@cdc.gov](mailto:omb@cdc.gov).

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

## Proposed Project

Hazardous Substances Emergency Events Surveillance (HSEES)—Extension—(0923-0008), Agency for Toxic Substances and Disease Registry (ATSDR), Centers for Disease Control and Prevention (CDC).

## Background and Brief Description

The Agency for Toxic Substances and Disease Registry (ATSDR) is mandated

pursuant to the 1980 Comprehensive Environmental Response Compensation and Liability Act (CERCLA) and its 1986 Amendments, The Superfund Amendments and Reauthorization Act (SARA), to prevent or mitigate adverse human health effects and diminished quality of life resulting from the exposure to hazardous substances into the environment. The primary purpose of this activity, which ATSDR has supported since 1992, is to develop, implement, and maintain a state-based surveillance system for hazardous substances emergency events which can be used to (1) describe the distribution of the hazardous substances releases; (2) describe the public health consequences (morbidity, mortality, and evacuations) associated with the events; (3) develop strategies to reduce future public health consequences. The study population will consist of all hazardous substance non permitted acute releases within the 14 states (Colorado, Florida, Iowa,

Louisiana, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Texas, Utah, Washington, and Wisconsin) participating in the surveillance system.

Until this system was developed and implemented, there was no national public health-based surveillance system to coordinate the collation, analysis, and distribution of hazardous substances emergency release data to public health practitioners. It was necessary to establish this national surveillance system which describes the public health impact of hazardous substances emergencies on the health of the population of the United States. The data collection form will be completed by the state health department Hazardous Substances Emergency Events Surveillance (HSEES) coordinator using a variety of sources including written and oral reports from environmental protection agencies, police, firefighters, emergency response

personnel; or researched by the HSEES coordinator using material safety data sheets, and chemical handbooks. There is a reduction in the annual burden hours per response because of the reduction in number of states from 15 to 14 and because of a change in the case definition of an HSEES event in 2005, which excludes stack emissions of oxides of nitrogen (NO<sub>x</sub>), oxides of sulfur (SO<sub>x</sub>), and carbon monoxide (CO) when they are not mixed with another hazardous substance.

The HSEES public use data set is available on the ATSDR HSEES Web site. Interested parties complete a brief description of who will be using the data and for what purpose in order to download the data. This allows ATSDR to widely distribute the data and track its usefulness.

There is no cost to the respondents other than their time.

**ESTIMATED ANNUALIZED BURDEN HOURS**

Respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
Participating State Health Department HSEES Coordinators .....	14	536	45/60	5,628
Persons interested in HSEES data through Web site .....	500	1	6/60	50
Total .....	514	.....	.....	5,678

Dated: January 4, 2008.  
**Marilyn S. Radke,**  
*Reports Clearance Officer, Centers for Disease Control and Prevention.*  
 [FR Doc. E8-270 Filed 1-9-08; 8:45 am]  
**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 2007D-0493]

**International Conference on Harmonisation; Draft Guidance on Q8(R1) Pharmaceutical Development; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled “Q8(R1) Pharmaceutical Development Revision 1.” The draft guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of

Pharmaceuticals for Human Use (ICH). The draft guidance is an annex to the parent ICH guidance entitled “Q8 Pharmaceutical Development” (71 FR 29344, May 22, 2006) (ICH Q8). It provides further clarification of key concepts outlined in ICH Q8 and describes the principles of quality by design (QbD). The draft guidance is intended to show how concepts and tools (e.g., design space) outlined in ICH Q8 could be put into practice by the applicant for all dosage forms.

**DATES:** Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit written or electronic comments on the draft guidance by April 9, 2008.

**ADDRESSES:** Submit written comments on the draft guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to either <http://www.fda.gov/dockets/ecomments> or <http://www.regulations.gov>. Submit written requests for single copies of the draft guidance to the Division of Drug

Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, or the Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448. The draft guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 301-827-1800. Send two self-addressed adhesive labels to assist the office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance and other guidances mentioned in this document.

**FOR FURTHER INFORMATION CONTACT:**  
*Regarding the guidance:* Moheb Nasr, Center for Drug Evaluation and Research (HFD-800), Food and Drug Administration, 10903 New Hampshire Ave., bldg. 21, rm. 2630, Silver Spring, MD 20993-0002, 301-796-1900; or Christopher Joneckis, Center for Biologics Evaluation and Research (HFM-20), Food and Drug Administration, 1401 Rockville Pike,